Mark Pithan, MD
Neurology · Kamuela, HINPI 1184680605
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,138 of the $1,326 with a category attached, or 85.8%. It is spread thinly across 32 manufacturers, the largest accounting for just 23.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $580 and has fallen 83.8% since, to $94 in 2025. That places this record below the midpoint for neurology clinicians in HI, where the typical reported total is $2,045.
Across 58 payments — averaging $22.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$313
- Novartis$130
- AbbVie$121
- MDD US Operations, LLC$72
- Biogen$65
- CSL Behring$49
- plus $575 from 26 others
What the payments were for
- Travel & lodging$18814%
- Food & beverage$1,13886%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 3 | $313 |
| Novartis | 8 | $130 |
| AbbVie(2 entities) | 6 | $121 |
| MDD US Operations, LLC | 3 | $72 |
| Biogen | 4 | $65 |
| CSL Behring | 3 | $49 |
| Amneal Pharmaceuticals LLC | 2 | $41 |
| Lundbeck LLC | 2 | $39 |
| Eisai Inc. | 2 | $36 |
| Axsome Therapeutics, Inc. | 2 | $35 |
| Argenx US, Inc. | 1 | $30 |
| Jazz Pharmaceuticals Inc. | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Mallinckrodt Enterprises LLC | 1 | $26 |
| Neurelis, Inc. | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 1 | $24 |
| AstraZeneca | 1 | $22 |
| EMD Serono, Inc. | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Philips North America LLC | 1 | $18 |
| Merz North America, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Abbott | 1 | $15 |
| Impel Pharmaceuticals Inc. | 1 | $15 |
| Sanofi | 1 | $14 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
| Medtronic | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Portola Pharmaceuticals, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$290
How this compares
$1,326 in reported general payments places this provider in the 45th percentile of 54 neurology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tetrabenazine | 11 | $75,578 |
| Emgality PenGalcanezumab-Gnlm | 21 | $17,621 |
| RytaryCarbidopa/Levodopa | 12 | $6,059 |
| Lacosamide | 16 | $3,187 |
| Gabapentin | 65 | $2,331 |
| Primidone | 42 | $2,088 |
| DilantinPhenytoin Sodium Extended | 12 | $1,222 |
| DilantinPhenytoin | 12 | $1,145 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 17 | $1,070 |
| Pregabalin | 27 | $1,026 |
| Levetiracetam | 49 | $930 |
| Propranolol Hcl ErPropranolol Hcl | 14 | $847 |
| Baclofen | 37 | $836 |
| Carbamazepine ErCarbamazepine | 13 | $804 |
| Oxcarbazepine | 15 | $674 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary | $41 | $6,05912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 54 neurology providers in Hawaii.
Other neurology in Kamuela
- Leo MaherHonolulu$382K
- David KaminskasKailua$120K
- Leah RidgeHonolulu$47K
- Melvin YeeHonolulu$32K
- Kevin KimataHonolulu$24K
- Terry ShimamotoHonolulu$24K
- Michael RussoHonolulu$20K
- Kore LiowHonolulu$15K
- Ray RomeroEwa Beach$13K
- Fay GaoHonolulu$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.